Want to see SE:ACOU full AI Analyst Report?
ACOU Stock Chart & Stats
kr2.64
-kr3.18(-45.56%)
At close: 4:00 PM EST
kr2.64
-kr3.18(-45.56%)
Day’s Range― - ―
52-Week Rangekr2.03 - kr5.16
Previous CloseN/A
Volume449.84K
Average Volume (3M)29.24K
Market Cap
kr75.56M
Enterprise Valuekr75.16M
Total Cash (Recent Filing)kr14.57M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding21,163,902
10 Day Avg. Volume27,764
30 Day Avg. Volume29,240
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr10.70M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces solvency risk and provides strategic flexibility to fund R&D, capital equipment, or partnerships without interest burden. Over 2–6 months this buffer supports execution of commercialization and lowers bankruptcy/liquidity tail risks versus leveraged peers.
Improving Revenue GrowthA rebound to ~8% TTM revenue growth signals improving commercial traction after weaker 2025. Sustained top-line momentum over coming quarters would help scale fixed-cost absorption, justify continued R&D and market development, and is a necessary precursor to durable profitability.
Proprietary Acoustic Separation TechAcouTrap’s acoustophoresis, label-free approach is a structural technology advantage for sensitive cell and particle handling. Its gentle, integration-friendly profile suits diagnostics and cell therapy workflows, creating a durable niche if clinical and bioprocess adopters validate the method.
Bears Say
Negative Gross Profit And Recurring LossesNegative gross profit and persistent operating/net losses indicate core unit economics are not yet viable. Without structural margin improvement through better yields, pricing, or lower COGS, ongoing losses will constrain reinvestment, slow commercialization, and prolong the path to sustainable profitability.
Negative And Declining Free Cash FlowOperating and free cash flow are negative with a steep FCF decline, signalling inconsistent cash generation. Even debt-free, continued cash burn forces reliance on equity raises or strategic partners, which can dilute shareholders or limit timely investment in commercialization and scale-up.
Eroding Equity And Very Negative ROEA TTM ROE near -80% and falling equity reflect value erosion from losses and cash burn. This reduces ability to attract capital on favorable terms, raises funding risk, and may force dilutive financing that impairs long-term shareholder value and constrains strategic optionality.
ACOU FAQ
What was AcouSort AB’s price range in the past 12 months?
AcouSort AB lowest stock price was kr2.03 and its highest was kr5.16 in the past 12 months.
What is AcouSort AB’s market cap?
AcouSort AB’s market cap is kr75.56M.
When is AcouSort AB’s upcoming earnings report date?
AcouSort AB’s upcoming earnings report date is Aug 26, 2026 which is in 32 days.
How were AcouSort AB’s earnings last quarter?
AcouSort AB released its earnings results on May 27, 2026. The company reported -kr0.112 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.112.
Is AcouSort AB overvalued?
According to Wall Street analysts AcouSort AB’s price is currently Overvalued.
Does AcouSort AB pay dividends?
AcouSort AB does not currently pay dividends.
What is AcouSort AB’s EPS estimate?
AcouSort AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AcouSort AB have?
AcouSort AB has 21,163,902 shares outstanding.
What happened to AcouSort AB’s price movement after its last earnings report?
AcouSort AB reported an EPS of -kr0.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.139%.
Which hedge fund is a major shareholder of AcouSort AB?
Currently, no hedge funds are holding shares in SE:ACOU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.
Technical Analysis
PILA PHARMA AB
―
OncoZenge AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―
Sprint Bioscience AB
―